Precigen Reports Fourth Quarter and Full Year 2020 Financial Results
- Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic -
- Strengthened balance sheet with successful public offering while streamlining operations and reducing operating costs -
- Initial data readouts from PRGN-3005 and PRGN-3006 UltraCAR-T® clinical trials demonstrated encouraging expansion, persistence and clinical activity -
- A PRGN-3006 UltraCAR-T patient achieved complete remission with incomplete hematologic recovery (CRi) per ELN criteria -
- Initiated first AdenoVerse™ immunotherapy clinical trial for PRGN-2009 in HPV-associated solid tumors -
- Interim data for AG019 ActoBiotics™ in T1D indicate encouraging trends in C-peptide levels and ability to induce antigen-specific immune modulation following only one treatment cycle of oral AG019 as monotherapy or combination -
Press Briefing by White House COVID-19 Response Team and Public Health Officials
MR. ZIENTS: Good morning. Thank you for joining us. We got very good news over the weekend: The Food and Drug Administration issued an emergency use authorization for a third safe and effective vaccine, the Johnson & Johnson vaccine, which will help us defeat the pandemic.
Published 01 March 2021
It’s now been 3.5 years since I last wrote anything about testicular germ cell tumors and ongoing clinical trials.
1 Although we still cure most men afflicted with this disease, we have not made any major new therapeutic advancements since I wrote that last article. Approximately, 15-20% of patients with metastatic germ cell tumors will relapse following initial chemotherapy. Even in this situation, approximately 50% can still be cured with salvage treatments, either with more conventional cisplatin-based chemotherapy or with high-dose chemotherapy and autologous stem cell rescue.
2-4 However, patients with cisplatin-refractory disease or progressive disease following high-dose salvage chemotherapy and autologous stem cell rescue, harbor an extremely dim prognosis. In these situations, palliative chemotherapy, with regimens containing oxaliplatin, is limited in efficacy, and targeted biologic therapies have also shown limited efficacy.
Announcing the PLOS Scientific Advisory Council - The Official PLOS Blog plos.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from plos.org Daily Mail and Mail on Sunday newspapers.
COVID-19: What B.C. can learn from Washington stateâs vaccine rollout After some early struggles, Washington has now administered more than 1.5 million doses of COVID-19 vaccine to its residents
Author of the article: Gordon Hoekstra
Publishing date: Feb 28, 2021  â¢Â March 2, 2021  â¢Â 3 minute read  â¢Â Dr. Stephaun Wallace, who leads the global external relations strategies COVID-19 Prevention Network at the Fred Hutchinson Cancer Research Center, receives his second injection from Dr. Tia Babu during the Novavax COVID-19 vaccine Phase 3 clinical trial at the UW Virology Research Clinic on Feb. 12 in Seattle. Photo by Karen Ducey /Getty Images
Article content
As B.C. begins to put in place the pieces to significantly ramp up and administer millions of vaccines starting in April, our next-door American neighbours may have some lessons to provide.